Halozyme director Connie Matsui to exit board

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company with a market capitalization of $7.4 billion, announced today that board member Connie L. Matsui has decided not to seek reelection at the upcoming 2025 annual meeting of stockholders. Matsui, who has been part of the Halozyme board for nearly 18 years, informed the company of her decision on Monday.

The company expressed its gratitude to Matsui for her long service and valuable contributions. Halozyme emphasized that her departure is not due to any disagreements regarding the company's operations, policies, practices, or strategy, nor with the company's management or the Board of Directors.

You May Also Be Interested In

• Kinetik adds Craig Harris to its board of directors
• Extra Space Storage prices $550 million senior notes offering at 4.900%
• Blue Moon Metals awards EPC contract, clears final Norway permits